Price transparency in healthcare has become more important as consumers increasingly engage in healthcare decision making and are asked to pay more for their care.
Price transparency in healthcare has become more important as consumers increasingly engage in healthcare decision making and are asked to pay more for their care. A new issue brief from America’s Health Insurance Plans (AHIP) takes a look at price transparency efforts, barriers to improved price transparency, and structuring future initiatives.
Making healthcare cost information readily available and usable by consumers is one way health plans and employers are hoping to improve efficiency, clinical effectiveness, and value.
“As a result of the increased recognition of the value of price transparency in informing consumer decision-making and promoting efficient, quality care, health plans, as well as the federal and state governments, have taken steps to increase the availability of price information for health care services and promote its use in consumer decision-making,” according to the AHIP issue brief.
There are really 2 main challenges to implementing price transparency in healthcare, according to the report. One challenge to greater price transparency is that the definition of cost may change depending on who is incurring the cost: the patient, the provider, the insurer, or the employer. The second challenge is simply availability of price information and public interest in using the data provided.
The use of price transparency tools has many benefits. For instance, price transparency for a procedure can reduce that procedure’s market price.
“Price transparency can also reduce claims payments for lab tests, advanced imaging, and clinician office visits, and reduce overall payments made for clinical care,” according to the issue brief.
AHIP also provided key elements that should be used to evolve initiatives and tools to make provider price information available:
“As price transparency initiatives and tools continue to evolve, stakeholders should pursue continued emphasis on the integration of quality information, given existing evidence that cost data, presented with quality data, can influence consumer decision-making and lead to value-based choices,” the brief concludes.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More